OmniClouds Standardizes on Versa Networks to Deliver Secure SD-WAN Across the Globe
14.9.2020 14:55:00 EEST | Business Wire | Press release
OmniClouds, the leading innovator in the cloud service provider (CSP) space and migrator for the EMEA region, today announced that it has adopted the Versa Secure SD-WAN solution to offer and expand services across the globe, using OmniClouds’ comprehensive SDN-dedicated network offering a unique experience of true SLA-based cloud services.
OmniClouds platform connects its enterprise customers’ branches and remote users to multiple public and private clouds, lowering the expense and complications of cloud adoption Globally. It is offering Versa Networks, the leader in Secure SD-WAN providing software-defined networking over any type of connectivity for simplified management and dynamic support for cloud adoption and migration.
OmniClouds will not only provide full hybrid cloud connectivity but will also use Versa Networks as an overlay to existing connectivity technologies, such as IP-MPLS, microwave, satellite, LTE or public internet, to automate operations and enhance connectivity over large geographic regions. This will give its enterprise, government and SME customers a central management view of the entire network, enabling them to easily control security, user permissions and parameters, such as latency and quality of service.
OmniClouds will use Versa Cloud Gateways at each of the regions’ and counties’ main cloud service providers, which connect with Secure SD-WAN CPE running Versa Operating System (VOS™) at the enterprises’ data centers, headquarters and branch operations. This dramatically reduces customer operating costs, smooths their adoption of cloud services, and enables widespread connectivity across distant locations.
Amr A Eid, Group Chief Executive Officer and Board Member, OmniClouds, said: “OmniClouds is excited and proud of the strategic partnership with Versa Networks, the best in class for SD-WAN Technologies. We are a partner led global organization, addressing our SME, Public Sector and SOHO customers through our regional, local, white label ISPs across the globe. In doing so we look for strong partnerships for our network technology and visionary and trustworthy leadership, and Versa Networks is exceptional in all these aspects. We are confident that we are setting the standard for both cloud connectivity and smart applications management.”
“OmniClouds is a leader in optimizing, migrating, and supporting organizations’ migration from traditional internet connectivity models to modern, cloud-based network infrastructures,” said Kelly Ahuja, CEO of Versa Networks. “Secure SD-WAN is the pervasive method for businesses and organizations to securely, reliably, and seamlessly connect their offices, teleworkers, employees, staff, and partners globally to private data centers, cloud services, and SaaS. Versa is excited to be working with OmniClouds to deliver the best-of-breed solution for the growing Middle East and Africa regions.”
Versa Networks, VOS, and Versa Titan are or may be registered trademarks of Versa Networks, Inc. All other marks and names mentioned herein may be trademarks of their respective companies.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005470/en/
Contact information
OmniClouds
Mr. Amr Eid
The Group CEO & Board member
media@omniclouds.com
Versa Networks
media@versa-networks.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom